Kura Oncology, Inc. — Q3 2016 Form 10-Q Summary
Business Context and Reporting Period
Kura Oncology is a clinical-stage biopharmaceutical company developing targeted small-molecule cancer therapies and companion diagnostics. The filing covers the three and nine months ended September 30, 2016, and was filed November 7, 2016. The company had 21.4 million common shares outstanding as of November 2, 2016.
- Lead candidate: tipifarnib, being evaluated in Phase 2 studies for HRAS-mutated solid tumors, peripheral T-cell lymphoma, lower-risk myelodysplastic syndromes, and chronic myelomonocytic leukemia.
- KO-947, an ERK inhibitor, was in preclinical IND-enabling development; management anticipated an IND submission in the fourth quarter of 2016 and a Phase 1 trial in the first half of 2017.
- The menin-MLL program remained in lead optimization, with candidate nomination targeted for the fourth quarter of 2016.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $5.3 million vs. $4.6 million | $14.9 million vs. $12.7 million |
| General and administrative expense | $1.7 million vs. $1.8 million | $6.0 million vs. $4.4 million |
| Net loss | $6.9 million vs. $6.1 million | $20.2 million vs. $16.2 million |
| Net loss per share | $0.37 vs. $0.57 | $1.09 vs. $1.98 |
| Cash used in operating activities | Not separately provided | $18.6 million vs. $12.3 million |
The filing does not provide a meaningful revenue or gross-margin measure because Kura had no approved products and no product sales. The company remained loss-making with an accumulated deficit of $46.5 million at September 30, 2016.
- Cash and cash equivalents: $6.8 million, compared with $15.4 million at December 31, 2015.
- Short-term investments: $67.8 million, compared with $70.3 million at year-end 2015.
- Total cash, cash equivalents and short-term investments: $74.6 million.
- Total assets: $76.3 million; total liabilities: $12.6 million; stockholders’ equity: $63.7 million.
- Long-term debt, net: $7.3 million, consisting of a $7.5 million Term A Loan less unamortized debt discount.
- Net cash provided by financing activities was $7.5 million, entirely from the term loan. No equity financing was completed during the first nine months of 2016.
Material Changes Versus the Prior Comparable Period
- Nine-month research and development expense increased $2.2 million, primarily from higher outsourced clinical development costs, outsourced research contracts and personnel costs. These increases were partly offset by lower license fees and share-based compensation.
- Nine-month general and administrative expense increased $1.6 million, reflecting higher public-company compliance, personnel, professional and consulting, and patent-related costs.
- Nine-month net loss increased $4.1 million, while operating cash use increased $6.3 million.
- Per-share loss improved because weighted-average shares increased substantially, from 8.1 million to 18.5 million for the nine-month periods, despite the higher absolute net loss.
- Interest expense increased following the April 2016 term loan, reducing other income to $0.7 million for the nine-month period from $0.9 million.
- Cash flow benefited from $43.7 million of marketable-security maturities, offset by $41.2 million of new purchases. The prior-year period included $47.6 million of common-stock proceeds and $5.0 million of convertible-note proceeds.
- The company implemented a new enterprise resource planning system during the quarter. Management stated that disclosure controls were effective and that the ERP-related changes had not materially affected internal control over financial reporting.
Guidance, Outlook, Risks and Unusual Items
- Management expected existing cash, cash equivalents and short-term investments to fund current operations into 2018, but stated that substantial additional financing will be required.
- The company could borrow up to an additional $12.5 million under its term loan facility between December 31, 2016 and May 1, 2017, subject to successfully advancing KO-947 into Phase 1 trials.
- The term loan bears interest at the greater of 7.75% or the applicable prime rate plus 4.25%, matures November 1, 2020, and is interest-only through May 1, 2018. It is secured by substantially all assets other than intellectual property and includes financial and operating covenants.
- The company was in compliance with material loan covenants at September 30, 2016. Default could permit acceleration of the debt and enforcement against pledged assets.
- Kura expects significant operating losses and negative operating cash flow for the foreseeable future and has no committed external funding source beyond the term loan facility.
- KO-947 manufacturing delays and formulation stability issues delayed the IND submission. Further manufacturing or formulation problems could delay or prevent clinical development.
- Key risks include clinical-trial failure or delay, difficulty identifying and enrolling biomarker-defined patients, regulatory non-approval, companion-diagnostic development risk, dependence on third-party manufacturers and CROs, intellectual-property limitations, additional capital needs, and potential stockholder dilution.
- Tipifarnib’s composition-of-matter patents had recently expired in the United States and certain European countries, increasing reliance on other patents and regulatory exclusivity.
- Related-party transactions with affiliates included $0.7 million of management-fee income for the first nine months, $3.2 million of related-party research and development expense, and $1.1 million of related-party accrued payables at September 30, 2016.
- No material legal proceedings or off-balance-sheet arrangements were reported.
Most Important Facts for Investors to Verify
- Whether the stated cash runway into 2018 remains adequate relative to the pace of clinical development spending and whether additional financing is required sooner.
- Progress, manufacturing readiness and regulatory timing for the KO-947 IND and planned Phase 1 trial.
- Enrollment rates, biomarker validation, efficacy and safety results in the four tipifarnib Phase 2 programs.
- Availability and conditions of the additional $12.5 million Term B borrowing capacity, including the KO-947 advancement requirement and related warrant issuance.
- Potential dilution from future equity or convertible financing, outstanding options, restricted awards and the 67,976 lender warrants.
- Dependence on Janssen and other licensors, including diligence obligations, royalties, patent rights and the risk of losing licensed rights.
- Accuracy and comparability of the reported per-share loss, given the substantial increase in weighted-average shares and the reverse-merger history.